MetLife, Inc. (MET) Stock: Price, Forecast & Analyst Target
MetLife, Inc. (MET) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $99.79 (-1.68%), as of the Nov 18, 2026 trading session; market cap $62.7B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
MetLife, Inc. · MET · NYSE · Financial Services · Insurance - Life
Research dated 2026-09-12: MetLife is a global insurer, employee-benefits provider, retirement-risk carrier and asset manager whose results depend on more than policy sales. The core question is whether recurring insurance and fee activity can support steadier earnings while investment returns and large contractual obligations keep reported profit volatile.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · MetLife (MET)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite growth, at a dirt-cheap price, though quality is only middling; the market is already moving on it. Business Quality: Average; Financial Safety: Sound; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 0.68 · Piotroski F 8
- ROE 19.9% · ROA 0.6% · current ratio 1.87
Helping: an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 92 | Exceptional | |
| 93 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $99.79 | |
| Change on the day | -1.68% | |
| 52-week range | $67.33–$106.72 | |
| Market capitalisation | $62.7B | — |
| Price / earnings (trailing) | 13.15 | |
| Shares traded on the day | 4.27M | |
| Beta (volatility vs the S&P 500) | 0.77 |
Why MetLife scores 88
Share price, last 12 months +31.7%
$77.18 $101.67
What the price assumes
-14.8% a year of free-cash-flow growth for ten years is what a $64.61B market value ( snapshot) asks for.
The price asks for less growth than the business has been producing. The question it leaves open is how long that pace lasts, not whether it exists.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $15.00B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 6 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 2.6% either way.
- -7.7%Jan ’24
- -1.2%May ’24
- -1.3%Jul ’24
- -5.3%Oct ’24
- -1.1%Feb ’25
- -0.9%Apr ’25
- -1.4%Aug ’25
- -4.4%Nov ’25
- -2.1%Feb ’26
- -1.4%May ’26
- +4.0%Aug ’26
- -0.9%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| In line | Beat | -0.9% | — | |
| Beat | Miss | +4.0% | +0.6% | |
| Beat | Beat | -1.4% | -2.3% | |
| Beat | Miss | -2.1% | +2.6% | |
| Beat | Miss | -4.4% | +0.9% | |
| Miss | Miss | -1.4% | +3.3% | |
| Miss | In line | -0.9% | +0.4% | |
| Miss | Miss | -1.1% | -2.2% | |
| Miss | Miss | -5.3% | +0.5% | |
| Beat | Miss | -1.3% | -10.4% | |
| In line | Miss | -1.2% | +0.8% | |
| Beat | Beat | -7.7% | -5.4% |
Misses cost real money here: the average first-session move after a miss was -2.2%.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “notable items”, “excluding notable”, “fixed income”, “actuarial assumption” — none of them came up in Q2 FY2026.
- Getting louder: “cash flow” (2 → 8 mentions), “attractive returns” (3 → 7 mentions), “free cash” (2 → 7 mentions).
- Gone quiet: “earnings power”, “region sales” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.5 to 1.9 per 1,000 words, and confident words such as “record” and “strong” fell from 8.8 to 7.4.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 89 to 88 while the share price moved +3.7% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 79% of 33 rate it a buy; the average target sits +8.9% from the price of $99.79.
- Last 90 days: 1 upgrade and 0 downgrades among 11 rating actions.
- Our signals: Exceptional band; strongest pillar Momentum (96), weakest Business Quality (52).
Here we and the crowd agree.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for MetLife (MET): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is MetLife (MET), and what does it report?
Short answer · as of
MetLife sells life and health protection, workplace benefits, annuities, pension risk transfers and investment products across the United States and several international regions.
Research dated 2026-09-12.
It also earns fees from administrative-only arrangements, vision services, prepaid legal plans and investment management, so revenue is not simply a measure of life-insurance premiums.
The income statement combines insurance activity, service fees and investment-sensitive businesses. The earnings measure compared with analyst estimates also differs materially from diluted earnings in the quarterly statement, making the underlying basis important when judging performance.
What do the latest results show for MetLife (MET)?
Research dated 2026-09-12.
Revenue softened from the preceding period, while operating profit, net income and diluted earnings fell more sharply. The latest consensus comparison was mixed: reported earnings cleared expectations, but revenue did not, after the preceding release had beaten expectations on each measure.
The available results establish the change but do not assign it to a particular operating cause. Management expects stronger private-equity returns, especially from venture holdings, as offering activity and public-market valuations improve; that is an outlook for investment contribution, not an explanation of the latest decline.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $20.52B Nov 4, 2026
- Latest report · revenue estimate
- $19.86B Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $20.52B | $19.86B | $2.7800 | $2.7700 |
| Aug 5, 2026 | $19.07B | $19.67B | $2.4300 | $2.3000 |
| May 6, 2026 | $19.68B | $19.49B | $2.4200 | $2.2700 |
| Feb 4, 2026 | $23.81B | $27.22B | $2.5800 | $2.3400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $16.88B | $896M | $1.22 (diluted) |
| Q4 FY2025 | $23.29B | $809M | $1.17 (diluted) |
| Q1 FY2026 | $18.62B | $1.19B | $1.74 (diluted) |
| Q2 FY2026 | $18.88B | $736M | $1.09 (diluted) |
What are the financial strengths and risks for MetLife (MET)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained positive across the reported periods, although its size varies considerably. Reported cash and short-term investments exceed debt, and the broader investment portfolio is substantial, but those assets sit inside an insurer carrying extensive policy and contractual liabilities; gross liquidity therefore should not be read as excess capital.
Profit is the more visible vulnerability. Annual revenue expanded while net income declined in the latest year, and quarterly margins remain modest, so changes in claims, credit experience or investment performance can have an outsized effect on equity returns even when revenue holds up.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.68 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at MetLife (MET)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12.
Watch whether MetLife converts management's expected improvement in private-equity returns into stronger reported profit without relying on revenue growth alone. The more durable confirmation would be firmer operating income and net income alongside continued positive operating cash flow.
The scheduled earnings release also provides a clean test of recent expectations: analysts anticipate expansion in revenue and earnings over the forecast horizon, while the latest release paired an earnings beat with a revenue miss. Continued divergence would make the definition and source of earnings increasingly important.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does MetLife compare with its peers?
Short answer
MetLife's score ranks 3rd of 12 in the bounded comparison shown, against 11 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
MetLife differs from a narrowly focused life insurer because workplace benefits, administrative contracts, pension risk transfers, annuities, institutional products and asset management all contribute to the economic model. Its geographic reach also spreads activity across the United States, Asia, Latin America, Europe, the Middle East and Africa.
That breadth creates several earnings channels, but it also links shareholder returns to investment markets and long-duration obligations as well as insurance demand. Comparisons based only on premium growth or a standard life-insurer multiple can miss those differences.
| Company | Price | Market value | Score |
|---|---|---|---|
| $294.92 Nov 18, 2026 | $8.95B | 96 5-pillar Nov 18, 2026 | |
| $20.86 Nov 18, 2026 | $3.77B | 96 5-pillar Nov 18, 2026 | |
| MetLife (MET) — this page | $99.79 | $62.7B | 88 |
| $121.54 Nov 18, 2026 | $41.7B | 85 5-pillar Nov 18, 2026 | |
| $42.22 Nov 19, 2026 | $69.8B | 79 5-pillar Nov 18, 2026 | |
| $55.02 Nov 19, 2026 | $5.03B | 78 5-pillar Nov 18, 2026 | |
| $155.15 Nov 18, 2026 | $11.7B | 74 5-pillar Nov 18, 2026 | |
| $124.77 Nov 19, 2026 | $61.7B | 65 5-pillar Nov 18, 2026 | |
| $42.07 Nov 18, 2026 | $8.01B | 61 5-pillar Nov 18, 2026 | |
| $76.39 Nov 18, 2026 | $11.8B | 56 5-pillar Nov 18, 2026 | |
| $24.78 Nov 19, 2026 | $30.2B | 48 5-pillar Nov 18, 2026 | |
| $14.77 Nov 18, 2026 | $2.49B | 31 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $103.00 – $112.00
- Consensus target
- $108.78
- Median target
- $110.00
Consensus record · Captured .
Measured against a quoted price of $99.79 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 51
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 1
- Other transactions
- 50
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MET in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.29% | $66.35M | Added +13.4% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about MetLife (MET)?
MET Financial Services Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does MetLife Group Benefits sell to employers?
Group Benefits supplies workplace protection such as life, dental, disability, vision, accident and health coverage, while administrative-only arrangements let employers retain some insurance risk and pay MetLife for administration.
Why do private-equity returns matter to MetLife earnings?
MetLife invests alongside its insurance and retirement businesses, so private-equity performance can affect investment contribution to profit. Management expects venture holdings to benefit from stronger offering activity and higher public-market valuations.
Is MetLife Holdings the same as the operating insurance business?
MetLife Holdings is a separately identified operating division within the wider company, which also reports businesses across the United States and international regions. The company therefore extends well beyond that portfolio.
Do MetLife insider records show open-market buying?
Recent insider activity is classified as awards and in-kind transactions, with no purchases or sales recorded in the stated window. That pattern describes transaction type, not insider intent.
What is the MET stock price today?
The last price recorded for MetLife, Inc. (MET), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MET price target?
The analyst consensus price target for MetLife, Inc. (MET), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 36 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold MET
Funds in our ETF coverage that list MET among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| RWW ETF | 3.84% |
